DZ Bank’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $332M | Buy |
2,628,110
+505,131
| +24% | +$66.6M | 0.25% | 93 |
|
|
2026
Q1 | $296M | Buy |
2,122,979
+80,154
| +4% | +$11.2M | 0.26% | 83 |
|
|
2025
Q4 | $251M | Buy |
2,042,825
+178,753
| +10% | +$21.7M | 0.22% | 93 |
|
|
2025
Q3 | $207M | Buy |
1,864,072
+1,322,560
| +244% | +$150M | 0.18% | 100 |
|
|
2025
Q2 | $60M | Buy |
541,512
+8,272
| +2% | +$880K | 0.06% | 156 |
|
|
2025
Q1 | $59.7M | Buy |
533,240
+233,166
| +78% | +$24.1M | 0.07% | 145 |
|
|
2024
Q4 | $27.7M | Sell |
300,074
-73,686
| -20% | -$6.63M | 0.03% | 207 |
|
|
2024
Q3 | $31.3M | Sell |
373,760
-21,467
| -5% | -$1.64M | 0.03% | 219 |
|
|
2024
Q2 | $27.1M | Buy |
395,227
+102,409
| +35% | +$6.83M | 0.03% | 226 |
|
|
2024
Q1 | $21.5M | Sell |
292,818
-45,175
| -13% | -$3.47M | 0.02% | 250 |
|
|
2023
Q4 | $27.4M | Sell |
337,993
-8,469
| -2% | -$659K | 0.03% | 227 |
|
|
2023
Q3 | $26M | Sell |
346,462
-479,705
| -58% | -$36.9M | 0.04% | 223 |
|
|
2023
Q2 | $63.7M | Sell |
826,167
-379,780
| -31% | -$30.3M | 0.1% | 126 |
|
|
2023
Q1 | $100M | Buy |
1,205,947
+554,330
| +85% | +$45.9M | 0.16% | 99 |
|
|
2022
Q4 | $55.9M | Buy |
651,617
+114,296
| +21% | +$9.05M | 0.09% | 141 |
|
|
2022
Q3 | $33.1M | Sell |
537,321
-38,180
| -7% | -$2.41M | 0.06% | 179 |
|
|
2022
Q2 | $35.6M | Sell |
575,501
-80,267
| -12% | -$4.97M | 0.06% | 182 |
|
|
2022
Q1 | $39M | Sell |
655,768
-275,827
| -30% | -$17.6M | 0.06% | 197 |
|
|
2021
Q4 | $68.1M | Buy |
931,595
+87,698
| +10% | +$6.04M | 0.05% | 205 |
|
|
2021
Q3 | $59M | Buy |
843,897
+145,585
| +21% | +$10.2M | 0.09% | 146 |
|
|
2021
Q2 | $48.1M | Buy |
698,312
+454,143
| +186% | +$30.3M | 0.08% | 168 |
|
|
2021
Q1 | $15.8M | Sell |
244,169
-279,899
| -53% | -$18M | 0.03% | 282 |
|
|
2020
Q4 | $29.9M | Sell |
524,068
-847,961
| -62% | -$51.2M | 0.06% | 190 |
|
|
2020
Q3 | $86.7M | Sell |
1,372,029
-31,020
| -2% | -$2.15M | 0.21% | 97 |
|
|
2020
Q2 | $108M | Sell |
1,403,049
-508,566
| -27% | -$39M | 0.29% | 77 |
|
|
2020
Q1 | $143M | Buy |
1,911,615
+387,821
| +25% | +$26.8M | 0.48% | 58 |
|
|
2019
Q4 | $99M | Buy |
1,523,794
+290,878
| +24% | +$18.9M | 0.26% | 84 |
|
|
2019
Q3 | $78.1M | Buy |
1,232,916
+23,750
| +2% | +$1.55M | 0.23% | 89 |
|
|
2019
Q2 | $81.7M | Sell |
1,209,166
-604,232
| -33% | -$39.7M | 0.25% | 91 |
|
|
2019
Q1 | $118M | Sell |
1,813,398
-71,563
| -4% | -$4.76M | 0.38% | 71 |
|
|
2018
Q4 | $117M | Sell |
1,884,961
-1,021,453
| -35% | -$71.4M | 0.45% | 67 |
|
|
2018
Q3 | $224M | Buy |
2,906,414
+1,621,623
| +126% | +$122M | 0.8% | 37 |
|
|
2018
Q2 | $91M | Sell |
1,284,791
-168,218
| -12% | -$11.9M | 0.34% | 85 |
|
|
2018
Q1 | $107M | Buy |
1,453,009
+322,677
| +29% | +$25.7M | 0.41% | 69 |
|
|
2017
Q4 | $81M | Buy |
1,130,332
+53,977
| +5% | +$4.1M | 0.31% | 91 |
|
|
2017
Q3 | $87.2M | Buy |
1,076,355
+50,192
| +5% | +$3.84M | 0.36% | 80 |
|
|
2017
Q2 | $72.6M | Buy |
1,026,163
+347,396
| +51% | +$23.1M | 0.34% | 87 |
|
|
2017
Q1 | $46.1M | Buy |
678,767
+215,523
| +47% | +$15.2M | 0.21% | 129 |
|
|
2016
Q4 | $33.2M | Buy |
+463,244
| New | +$34.4M | 0.16% | 155 |
|
Other funds holding GILD
DZ Bank's GILD Position: Q2 2026 in Review
DZ Bank increased its Gilead Sciences (GILD) stake by 24% in Q2 2026, buying an estimated $66.6M and bringing the position to 2,628,110 shares worth $332M. The position accounts for 0.25% of the portfolio, ranked #93.
DZ Bank first reported a position in GILD in Q4 2016 and has held it in 39 quarters since. 2,274 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- DZ Bank held 2,628,110 shares of Gilead Sciences worth $332M as of Q2 2026.
- DZ Bank bought 505,131 Gilead Sciences shares in Q2 2026, an estimated $66.6M.
- Gilead Sciences made up 0.25% of DZ Bank's portfolio in Q2 2026, its #93 holding.
- DZ Bank first reported a position in Gilead Sciences in Q4 2016 and has held it in 39 quarters since.
- 2,274 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on DZ Bank's 13F filing for Q2 2026, filed 14 Aug 2026.